Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223959 | 0.87 | LMNA (0.62) | CHRNB2CHRNA4LMNATDP1 | |
| SCHEMBL10272949 | 0.85 | CHRNB2 (0.55) | CHRNB2CHRNA4MAPK1TDP1TSHR | |
| SCHEMBL10224056 | 0.83 | GGPS1 (0.46) | MAPK1LMNATSHR | |
| SCHEMBL10224068 | 0.81 | GGPS1 (0.48) | CHRNB2CHRNA4MAPK1TSHR | |
| SCHEMBL10224093 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4MAPK1LMNATDP1 | |
| SCHEMBL12866793 | 0.81 | GGPS1 (0.50) | MAPK1TDP1TSHR | |
| SCHEMBL12775663 | 0.78 | ALDH1A1 (0.48) | CHRNB2CHRNA4MAPK1TDP1TSHR | |
| SCHEMBL12667879 | 0.78 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL10223981 | 0.78 | GGPS1 (0.42) | CHRNB2CHRNA4MAPK1NPSR1TDP1 | |
| SCHEMBL10235855 | 0.77 | TSHR (0.52) | CHRNB2CHRNA4MAPK1NPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | CHRNB2 3321/4885CHRNA4 3917/4885MAPK1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.